Search For
12 result(s) for 'Pancreatic cancer'
The BET inhibitor sensitivity is associated with the expression level of CDC25B in pancreatic cancer models
Open Access Original Article 18 Oct 2024
DOI: 10.20517/cdr.2024.53
Views: Downloads:
Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer
Open Access Review 31 Jan 2024
DOI: 10.20517/cdr.2023.84
Views: Downloads:
Major hurdles of immune-checkpoint inhibitors in pancreatic ductal adenocarcinoma
Open Access Commentary 30 May 2023
Views: Downloads:
Fungal mycobiome-mediated immune response: a non-negligible promoter in pancreatic oncogenesis and chemoresistance
Open Access Commentary 10 May 2023
DOI: 10.20517/cdr.2023.06
Views: Downloads:
Discovery of the inhibitor of DNA binding 1 as a novel marker for radioresistance in pancreatic cancer using genome-wide RNA-seq
Open Access Original Article 18 Oct 2022
DOI: 10.20517/cdr.2022.60
Views: Downloads:
Targeting the complement system in pancreatic cancer drug resistance: a novel therapeutic approach
Open Access Review 3 Apr 2022
Views: Downloads:
SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance
Open Access Original Article 8 Oct 2021
DOI: 10.20517/cdr.2021.61
Views: Downloads:
Overcoming acquired chemo-resistance to gemcitabine: implications from the perspective of multi-modal therapy including surgery for pancreatic cancer
Open Access Commentary 7 Sep 2021
DOI: 10.20517/cdr.2021.75
Views: Downloads:
The implication of liquid biopsies to predict chemoresistance in pancreatic cancer
Open Access Review 14 Apr 2021
DOI: 10.20517/cdr.2021.01
Views: Downloads:
Views: Downloads:
The dark side of immunotherapy: pancreatic cancer
Open Access Review 11 May 2020
DOI: 10.20517/cdr.2020.13
Views: Downloads:
Antibody drug conjugate development in gastrointestinal cancers: hopes and hurdles from clinical trials
Open Access Review 19 Dec 2018
DOI: 10.20517/cdr.2018.16
Views: Downloads:
- 1